文献速递甲状腺疾病

一项前瞻性队列研究探索仑伐替尼计划性药物假对分化型甲状腺癌治疗的影响

A Prospective Cohort Study Exploring the Effect of Lenvatinib Planned Drug Holidays in Treatment of Differentiated Thyroid Cancer.
PubMed 文献 · Thyroid · 2024-04-17

COLLECT前瞻性观察研究的事后分析纳入262例放射性碘难治性分化型甲状腺癌患者,仑伐替尼24 mg每日口服,253例可评估疗效者中73例由主治医师决定采用计划性药物假。药物假组的总生存、治疗失败时间、失败策略时间和无进展生存均显著长于未采用者,1年总生存率95.8%、1年无进展生存率94.5%。

要点

  • 在COLLECT研究可评估疗效的253例中,73例由主治医师决定采用计划性药物假。
  • 计划性药物假组的总生存、治疗失败时间、失败策略时间和无进展生存均显著长于未采用组。
  • 计划性药物假组1年总生存率95.8%,1年无进展生存率94.5%。

核心结论

  • 仑伐替尼计划性药物假与显著改善的临床结局相关,优于每日口服给药。
  • 作者认为有必要进一步研究仑伐替尼的最佳治疗方案。

研究设计与样本

  • COLLECT研究为前瞻性观察研究,患者在真实临床环境中接受仑伐替尼治疗。
  • 仑伐替尼口服剂量为每日24 mg,允许因毒性进行剂量调整。
  • 允许采用计划性药物假以避免严重或不可耐受的毒性。
  • 本分析为事后分析,评估计划性药物假对总生存、治疗失败时间、失败策略时间和无进展生存的影响。
  • 共纳入262例患者,其中253例可评估疗效,73例由主治医师决定采用计划性药物假。

主要发现

  • 计划性药物假组的总生存、治疗失败时间、失败策略时间和无进展生存均显著长于未采用组。
  • 计划性药物假组1年总生存率为95.8%,1年无进展生存率为94.5%。
  • 计划性药物假组在临床结局上显示出有临床意义的优势。
  • 计划性药物假组以≥10 mg剂量给药的持续时间显著更长。

局限性

  • 原文为事后分析,计划性药物假由主治医师决定。
  • 作者认为有必要进一步研究仑伐替尼的最佳治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Although lenvatinib is the preferred treatment for unresectable radioactive iodine-refractory differentiated thyroid cancer (RR-DTC), this agent exerts considerable toxicities, which can lead to frequent dose interruptions and modifications. The adoption of planned drug holidays has been recently suggested as one means of minimizing or avoiding these severe adverse events. Our retrospective study demonstrated that planned drug holidays appear to be a promising strategy for continuing of lenvatinib. However, the benefits of planned drug holidays in a prospective study have yet to be clarified. Here, we investigated the impact of planned drug holidays on clinical outcomes in patients treated with lenvatinib in the COLLECT study. Methods: In COLLECT, a prospective observational study, patients with RR-DTC were treated with lenvatinib in a real-world clinical setting. Lenvatinib was administered orally at a dose of 24 mg daily. Dose modification for toxicities was permitted. Furthermore, planned drug holidays were allowed to avoid severe or intolerable toxicities. The present post hoc analysis focused on evaluating the impact of planned drug holidays on clinical outcomes, including overall survival (OS), time to treatment failure (TTF), time to failure strategy (TFS), and progression-free survival (PFS), in patients in the COLLECT study who were treated with lenvatinib. Results: In total, 262 patients were included. Of the 253 patients evaluable for efficacy, 73 undertook a planned drug holiday at the discretion of the attending physician. OS, TTF, TFS, and PFS were significantly longer in patients who used a planned drug holiday than in those who did not. The planned drug holiday group demonstrated notable clinical outcomes, with a 1-year OS of 95.8% and a 1-year PFS of 94.5%. Moreover, planned drug holidays demonstrated a clinically meaningful advantage in clinical outcomes. The planned drug holiday group had a significantly longer duration of administration at a dose of ≥10 mg. Conclusions: Planned drug holidays for lenvatinib were associated with significantly improved clinical outcomes compared to daily oral administration. Further investigation of the optimal treatment schedule for lenvatinib is warranted. Clinical Trial Registration: UMIN000022243.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Tahara M, Takami H, Ito Y, et al. A Prospective Cohort Study Exploring the Effect of Lenvatinib Planned Drug Holidays in Treatment of Differentiated Thyroid Cancer. Thyroid. 2024. PMID: 38629757. doi:10.1089/thy.2023.0553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。